TY - JOUR
T1 - Post-COVID-19 persistent headache
T2 - A multicentric 9-months follow-up study of 905 patients
AU - Garcia-Azorin, David
AU - Layos-Romero, Almudena
AU - Porta-Etessam, Jesús
AU - Membrilla, Javier A.
AU - Caronna, Edoardo
AU - Gonzalez-Martinez, Alicia
AU - Mencia, Álvaro Sierra
AU - Segura, Tomás
AU - Gonzalez-García, Nuria
AU - Díaz-de-Terán, Javier
AU - Gallardo, Victor J.
AU - Gago-Veiga, Ana Beatriz
AU - Ballvé, Alejandro
AU - Trigo López, Javier
AU - Sastre-Real, María
AU - Llauradó, Arnau
AU - Cornejo, Ana
AU - de Lorenzo, Íñigo
AU - Guerrero-Peral, Ángel
AU - Pozo-Rosich, Patricia
N1 - Funding Information:
The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Data from one of the cohorts was funded by the regional health administration (Gerencia Regional de Salud (GRS) Castilla y Leon, grant number 2289/A/2020).
Funding Information:
The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: DGA received a research grant from the Regional Health Administration and an educational grant from the International Headache Society, and honoraria from the World Health Organization. PP-R has received honoraria as a consultant and speaker during the last 5 years from Allergan/AbbVie, Almirall, Biohaven, Chiesi, Corpus, Eli Lilly, Medscape, Neurodiem, Novartis and Teva. Her research group has received research grants from Novartis and Teva Pharmaceuticals and has received funding for clinical trials from Alder, electroCore, Eli Lilly, Lundbeck, Teva Pharmaceuticals, and Amgen/Novartis. She is a member of the Board of Trustees of the International Headache Society and a member of the Council of the European Headache Federation. She is on the editorial board of Revista de Neurologia. She is an associate editor for Cephalalgia, Headache, Neurologia, Frontiers of Neurology and The Journal of Headache and Pain. She is a member of the Clinical Trials Guidelines Committee of the International Headache Society. She has edited the Guidelines for the Diagnosis and Treatment of Headache of the Spanish Neurological Society. She does not own stocks from any pharmaceutical company. The rest of the authors declares no conflicts of interest.
Funding Information:
The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Data from one of the cohorts was funded by the regional health administration (Gerencia Regional de Salud (GRS) Castilla y Leon, grant number 2289/A/2020).
Publisher Copyright:
© International Headache Society 2022.
PY - 2022/7
Y1 - 2022/7
N2 - Background: Headache is a frequent symptoms of coronavirus disease 2019 (COVID-19). Its long-term evolution remains unknown. We aim to evaluate the long-term duration of headache in patients that presented headache during the acute phase of COVID-19. Methods: This is a post-hoc multicenter ambisective study including patients from six different third-level hospitals between 1 March and 27 April 2020. Patients completed 9 months of neurological follow-up. Results: We included 905 patients. Their median age was 51 (IQR 45–65), 66.5% were female, and 52.7% had a prior history of primary headache. The median duration of headache was 14 (6–39) days; however, the headache persisted after 3 months in 19.0% (95% CI: 16.5–21.8%) and after 9 months in 16.0% (95% confidence interval: 13.7–18.7%). Headache intensity during the acute phase was associated with a more prolonged duration of headache (Hazard ratio 0.655; 95% confidence interval: 0.582–0.737). Conclusion: The median duration of headache was 2 weeks, but in approximately a fifth of patients it became persistent and followed a chronic daily pattern.
AB - Background: Headache is a frequent symptoms of coronavirus disease 2019 (COVID-19). Its long-term evolution remains unknown. We aim to evaluate the long-term duration of headache in patients that presented headache during the acute phase of COVID-19. Methods: This is a post-hoc multicenter ambisective study including patients from six different third-level hospitals between 1 March and 27 April 2020. Patients completed 9 months of neurological follow-up. Results: We included 905 patients. Their median age was 51 (IQR 45–65), 66.5% were female, and 52.7% had a prior history of primary headache. The median duration of headache was 14 (6–39) days; however, the headache persisted after 3 months in 19.0% (95% CI: 16.5–21.8%) and after 9 months in 16.0% (95% confidence interval: 13.7–18.7%). Headache intensity during the acute phase was associated with a more prolonged duration of headache (Hazard ratio 0.655; 95% confidence interval: 0.582–0.737). Conclusion: The median duration of headache was 2 weeks, but in approximately a fifth of patients it became persistent and followed a chronic daily pattern.
KW - COVID-19
KW - Headache disorders
KW - migraine
KW - post-COVID
KW - secondary
UR - http://www.scopus.com/inward/record.url?scp=85125049293&partnerID=8YFLogxK
U2 - 10.1177/03331024211068074
DO - 10.1177/03331024211068074
M3 - Article
C2 - 35166156
AN - SCOPUS:85125049293
SN - 0333-1024
VL - 42
SP - 804
EP - 809
JO - Cephalalgia
JF - Cephalalgia
IS - 8
ER -